Client News

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Advancement of Izicopan in ANCA Associated Vasculitis and Select Renal Diseases

Mallia Therapeutics Announces Publication and Congress Presentation on Accelerated Wound Healing with sCD83

Neuvasq Presents Data Showcasing Promising Novel Multispecific Gpr124-Targeting Antibodies for Blood Retina Barrier Restoration at ARVO 2026

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

InflaRx to Report First Quarter 2026 Results on May 7, 2026

MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis

Tacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the Clinic

CorTec’s Brain Interchange™ BCI System Enables Stroke Patient to Control Computer with his Mind

DINAMIQS receives Swissmedic license for viral vector manufacturing and testing